vs

Side-by-side financial comparison of RECURSION PHARMACEUTICALS, INC. (RXRX) and Star Equity Holdings, Inc. (STRR). Click either name above to swap in a different company.

Star Equity Holdings, Inc. is the larger business by last-quarter revenue ($56.8M vs $35.5M, roughly 1.6× RECURSION PHARMACEUTICALS, INC.). Star Equity Holdings, Inc. runs the higher net margin — -3.0% vs -304.2%, a 301.2% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 69.0%). Star Equity Holdings, Inc. produced more free cash flow last quarter ($-9.0M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 29.5%).

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

Artists Equity is an American production company founded by actors and filmmakers Ben Affleck and Matt Damon in November 2022.

RXRX vs STRR — Head-to-Head

Bigger by revenue
STRR
STRR
1.6× larger
STRR
$56.8M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+612.7% gap
RXRX
681.7%
69.0%
STRR
Higher net margin
STRR
STRR
301.2% more per $
STRR
-3.0%
-304.2%
RXRX
More free cash flow
STRR
STRR
$38.4M more FCF
STRR
$-9.0M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
29.5%
STRR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RXRX
RXRX
STRR
STRR
Revenue
$35.5M
$56.8M
Net Profit
$-108.1M
$-1.7M
Gross Margin
59.8%
Operating Margin
-304.8%
-0.2%
Net Margin
-304.2%
-3.0%
Revenue YoY
681.7%
69.0%
Net Profit YoY
39.6%
-192.1%
EPS (diluted)
$-0.17
$-0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RXRX
RXRX
STRR
STRR
Q4 25
$35.5M
$56.8M
Q3 25
$5.2M
$48.0M
Q2 25
$19.2M
$35.5M
Q1 25
$14.7M
$31.9M
Q4 24
$4.5M
$33.6M
Q3 24
$26.1M
$36.9M
Q2 24
$14.4M
$35.7M
Q1 24
$13.8M
$33.9M
Net Profit
RXRX
RXRX
STRR
STRR
Q4 25
$-108.1M
$-1.7M
Q3 25
$-162.3M
$-1.8M
Q2 25
$-171.9M
$-688.0K
Q1 25
$-202.5M
$-1.8M
Q4 24
$-178.9M
$-585.0K
Q3 24
$-95.8M
$-846.0K
Q2 24
$-97.5M
$-441.0K
Q1 24
$-91.4M
$-2.9M
Gross Margin
RXRX
RXRX
STRR
STRR
Q4 25
59.8%
Q3 25
-183.8%
43.0%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
50.5%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
RXRX
RXRX
STRR
STRR
Q4 25
-304.8%
-0.2%
Q3 25
-3327.6%
-3.4%
Q2 25
-916.8%
-0.6%
Q1 25
-1297.9%
-5.4%
Q4 24
-4042.4%
-0.4%
Q3 24
-377.1%
-1.2%
Q2 24
-697.4%
-0.5%
Q1 24
-698.4%
-9.0%
Net Margin
RXRX
RXRX
STRR
STRR
Q4 25
-304.2%
-3.0%
Q3 25
-3135.3%
-3.7%
Q2 25
-894.2%
-1.9%
Q1 25
-1373.3%
-5.5%
Q4 24
-3935.5%
-1.7%
Q3 24
-367.5%
-2.3%
Q2 24
-676.6%
-1.2%
Q1 24
-662.4%
-8.6%
EPS (diluted)
RXRX
RXRX
STRR
STRR
Q4 25
$-0.17
$-0.49
Q3 25
$-0.36
$-0.54
Q2 25
$-0.41
$-0.23
Q1 25
$-0.50
$-0.59
Q4 24
$-0.56
$-0.21
Q3 24
$-0.34
$-0.28
Q2 24
$-0.40
$-0.15
Q1 24
$-0.39
$-0.95

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RXRX
RXRX
STRR
STRR
Cash + ST InvestmentsLiquidity on hand
$743.3M
$10.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$1.1B
$65.7M
Total Assets
$1.5B
$113.2M
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RXRX
RXRX
STRR
STRR
Q4 25
$743.3M
$10.3M
Q3 25
$659.8M
$15.4M
Q2 25
$525.1M
$16.8M
Q1 25
$500.5M
$16.6M
Q4 24
$594.4M
$17.0M
Q3 24
$427.6M
$15.8M
Q2 24
$474.3M
$14.7M
Q1 24
$296.3M
$20.4M
Total Debt
RXRX
RXRX
STRR
STRR
Q4 25
$9.6M
Q3 25
$11.9M
$6.5M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
$0
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
RXRX
RXRX
STRR
STRR
Q4 25
$1.1B
$65.7M
Q3 25
$1.0B
$67.8M
Q2 25
$919.1M
$40.1M
Q1 25
$933.9M
$39.5M
Q4 24
$1.0B
$40.4M
Q3 24
$524.6M
$42.9M
Q2 24
$584.4M
$42.6M
Q1 24
$401.2M
$44.3M
Total Assets
RXRX
RXRX
STRR
STRR
Q4 25
$1.5B
$113.2M
Q3 25
$1.4B
$117.1M
Q2 25
$1.3B
$55.6M
Q1 25
$1.3B
$53.2M
Q4 24
$1.4B
$52.6M
Q3 24
$726.5M
$52.6M
Q2 24
$775.9M
$52.6M
Q1 24
$557.8M
$52.6M
Debt / Equity
RXRX
RXRX
STRR
STRR
Q4 25
0.01×
Q3 25
0.01×
0.10×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
0.00×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RXRX
RXRX
STRR
STRR
Operating Cash FlowLast quarter
$-46.1M
$-7.3M
Free Cash FlowOCF − Capex
$-47.3M
$-9.0M
FCF MarginFCF / Revenue
-133.1%
-15.8%
Capex IntensityCapex / Revenue
3.5%
3.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M
$-13.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RXRX
RXRX
STRR
STRR
Q4 25
$-46.1M
$-7.3M
Q3 25
$-117.4M
$-2.7M
Q2 25
$-76.4M
$139.0K
Q1 25
$-132.0M
$-802.0K
Q4 24
$-115.4M
$-2.8M
Q3 24
$-59.2M
$1.3M
Q2 24
$-82.2M
$-4.3M
Q1 24
$-102.3M
$-1.8M
Free Cash Flow
RXRX
RXRX
STRR
STRR
Q4 25
$-47.3M
$-9.0M
Q3 25
$-117.6M
$-3.4M
Q2 25
$-79.6M
$102.0K
Q1 25
$-133.8M
$-808.0K
Q4 24
$-116.7M
$-2.8M
Q3 24
$-63.8M
$1.3M
Q2 24
$-83.4M
$-4.3M
Q1 24
$-109.0M
$-1.8M
FCF Margin
RXRX
RXRX
STRR
STRR
Q4 25
-133.1%
-15.8%
Q3 25
-2272.5%
-7.0%
Q2 25
-413.9%
0.3%
Q1 25
-907.4%
-2.5%
Q4 24
-2567.7%
-8.3%
Q3 24
-244.6%
3.4%
Q2 24
-578.5%
-12.0%
Q1 24
-789.9%
-5.3%
Capex Intensity
RXRX
RXRX
STRR
STRR
Q4 25
3.5%
3.0%
Q3 25
4.7%
1.3%
Q2 25
16.4%
0.1%
Q1 25
12.4%
0.0%
Q4 24
28.6%
0.1%
Q3 24
17.5%
0.0%
Q2 24
8.2%
0.0%
Q1 24
48.2%
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RXRX
RXRX

Segment breakdown not available.

STRR
STRR

Revenue From Other Contracts With Customers$27.6M49%
Other$24.3M43%
Energy Services Segment$4.9M9%

Related Comparisons